Skip to content

Torsion Optimization to Reduce Symptoms and Improve Outcomes in Non-responders

Torsion Optimization to Reduce Symptoms and Improve Outcomes in Non-responders (TORSION). A Randomized Comparison of Torsion-imaging Guided Optimization vs. Usual Settings.

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00867984
Acronym
TORSION
Enrollment
60
Registered
2009-03-24
Start date
2009-03-31
Completion date
2017-01-31
Last updated
2015-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure, Congestive

Keywords

CRT, resynchronization,

Brief summary

Approximately 40% of resynchronization therapy recipients do not appear to clearly benefit. These patients are termed 'non-responders'. This study will assess whether a heart ultrasound (echo) technique called 'torsion imaging' can be used to increase the likelihood of benefit from resynchronization therapy.

Detailed description

Background: Despite advances in pharmacotherapy, patients with heart failure (HF) are at high risk for death and hospitalization. Over 25% of patients with systolic HF have dyssynchronous ventricular contraction that impairs left ventricular (LV) function and results in HF progression. Cardiac resynchronization therapy (CRT) is designed to synchronize ventricular mechanical activity, improving cardiac output and reducing HF symptoms. As shown in our pilot data, at least 40% of patients do not respond to CRT despite pre-screening for the presence of longitudinal (long axis) mechanical (velocity) dyssynchrony and targeting LV lead placement to the latest site of latest velocity. Methods to improve the rates of response to CRT are required. Torsion imaging guided optimization of CRT timing is a promising approach and will be tested in this study. Primary hypothesis: Optimization of inter-ventricular (VV) timing, guided by torsion imaging, will increase functional capacity and reduce LV end systolic volume \[ESV\] in CRT in patients who have not responded after ≥ 6 months. CRT response will be defined by a ≥ 1 functional class improvement and either a ≥ 10% reduction in LV ESV or a ≥ 5% increase in EF at follow-up versus baseline. Secondary aims: To compare the following in torsion-guided vs usual care patients: a) echo parameters (intra-LV and VV dyssynchrony and torsion, and mitral regurgitation), b) N-terminal BNP levels, and c) generic / disease-specific quality of life. Methods: Randomized study of patients who have not responded to CRT after ≥ 6 months.

Interventions

OTHERTorsion optimized

Torsion optimized VV timing plus AV optimization (VTI)

OTHERUsual Care

AV optimization (VTI) only

Sponsors

Heart and Stroke Foundation of Canada
CollaboratorOTHER
University of Calgary
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* non-response to CRT as indicated, * stable doses of ACE I / ARB and beta-blocker for ≥ 2 months, & * controlled heart rate if in atrial fibrillation.

Exclusion criteria

* inadequate images to assess torsion * no significant augmentation in torsion with optimization * unable or unwilling to provide informed consent, * medical condition other than HF likely to cause death within 6 months, * cardiac transplant planned, * myocardial infarction or revascularization since CRT implant.

Design outcomes

Primary

MeasureTime frame
Improved functional class (≥ 1 class) & remodeling (either ≥ 10% relative reduction in LV ESV or a ≥ 5% absolute increase in LV EF).Follow up (3-6 months) versus baseline.

Secondary

MeasureTime frame
dyssynchrony and torsionFollow-up (3-6 months) vs. baseline
mitral regurgitationFollow-up (3-6 months) vs. baseline
N-terminal BNP levelFollow-up (3-6 months) vs. baseline
quality of lifeFollow-up (3-6 months) vs. baseline

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026